Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27–28, 2017, Tours, France

References

• Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody–drug conjugates. Nat Rev Drug Discov. 2017;16:315–37. doi:10.1038/nrd.2016.268. PMID:28303026.
   PubMed Web of Science ®Google Scholar
• Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, Singh R. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem. 2010;21:84–92. doi:10.1021/bc900315y. PMID:19891424.
   PubMed Web of Science ®Google Scholar
• Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, LaBelle A, Payne G, Lutz RJ, Pinkas J, et al. IMGN853, a Folate Receptor-α (FRα)-Targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FRα-Expressing tumors. Mol Cancer Ther. 2015;14:1605–13. doi:10.1158/1535-7163.MCT-14-1095. PMID:25904506.
   PubMed Web of Science ®Google Scholar
• Miller ML, Fishkin NE, Li W, Whiteman KR, Kovtun Y, Reid EE, Archer KE, Maloney EK, Audette CA, Mayo MF, et al. A new class of antibody-drug conjugates with potent DNA alkylating activity. Mol Cancer Ther. 2016;15:1870–8. doi:10.1158/1535-7163.MCT-16-0184. PMID:27216304.
   PubMed Web of Science ®Google Scholar
• Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJM, Bezabeh BZ, Fleming RL, Dimasi N, et al. A Biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell. 2016;29:117–29. doi:10.1016/j.ccell.2015.12.008. PMID:26766593.
   PubMed Web of Science ®Google Scholar
• Dimasi N, Fleming R, Zhong H, Bezabeh B, Kinneer K, Christie RJ, Fazenbaker C, Wu H, Gao C. Efficient preparation of site-specific antibody-drug conjugates using cysteine insertion. Mol Pharm. 2017;14:1501–16. doi:10.1021/acs.molpharmaceut.6b00995. PMID:28245132.
   PubMedGoogle Scholar
• Beerli RR, Hell T, Merkel AS, Grawunder U. Sortase enzyme-mediated generation of site-specifically conjugated antibody drug conjugates with high In Vitro and In Vivo potency. PLoS One. 2015;10:1–17. doi:10.1371/journal.pone.0131177.
   Web of Science ®Google Scholar
• Stefan N, Gébleux R, Waldmeier L, Hell T, Escher M, Wolter FI, Grawunder U, Beerli RR. Highly potent, anthracycline-based antibody-drug conjugates generated by enzymatic, site-specific conjugation. Mol Cancer Ther. 2017;16:879–92. doi:10.1158/1535-7163.MCT-16-0688. PMID:28258164.
   PubMed Web of Science ®Google Scholar
• Le Clorennec C, Bazin H, Dubreuil O, Larbouret C, Ogier C, Lazrek Y, Garambois V, Poul M-A, Mondon P, Barret J-M, et al. Neuregulin 1 allosterically enhances the anti-tumor effects of the non-competing anti-HER3 antibody 9F7-F11 by increasing its binding to HER3. Mol Cancer Ther. 2017;16:1312–23. doi:10.1158/1535-7163.MCT-16-0886. PMID:28507002.
   PubMed Web of Science ®Google Scholar
• Le Clorennec C, Lazrek Y, Dubreuil O, Larbouret C, Poul MA, Mondon P, Melino G, Pelegrin A, Chardes T. The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation. Oncotarget. 2016;7:37013–29. doi:10.18632/oncotarget.9455. PMID:27203743.
   PubMed Web of Science ®Google Scholar
• Adams SR, Yang HC, Savariar EN, Aguilera J, Crisp JL, Jones KA, Whitney MA, Lippman SM, Cohen EEW, Tsien RY, et al. Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. Nat Commun. 2016;7:13019. doi:10.1038/ncomms13019. PMID:27698471.
   PubMed Web of Science ®Google Scholar
• Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology. 2017;6:e1277306. doi:10.1080/2162402X.2016.1277306. PMID:28405498.
   PubMed Web of Science ®Google Scholar
• Deonarain MP, Yahioglu G, Stamati I, Marklew J. Emerging formats for next-generation antibody drug conjugates. Expert Opin Drug Discov. 2015;10:463–81. doi:10.1517/17460441.2015.1025049. PMID:25797303.
   PubMed Web of Science ®Google Scholar
• Dammicco S, Goux M, Lemaire C, Becker G, Bahri MA, Plenevaux A, Cinier M, Luxen A. Regiospecific radiolabelling of Nanofitin on Ni magnetic beads with [18F]FBEM and in vivo PET studies. Nucl Med Biol. 2017;51:33–9. doi:10.1016/j.nucmedbio.2017.04.006. PMID:28575696.
   PubMed Web of Science ®Google Scholar
• Goux M, Becker G, Gorré H, Dammicco S, Desselle A, Egrise D, Leroi N, Lallemand F, Bahri MA, Doumont G, et al. Nanofitin as a new molecular-imaging agent for the diagnosis of epidermal growth factor receptor over-expressing tumors. Bioconjug Chem. 2017;28:2361–71. doi:10.1021/acs.bioconjchem.7b00374. PMID:28825794.
   PubMed Web of Science ®Google Scholar
• Soranzo T, Cortès S, Gilde F, Kreir M, Picart C, Lenormand JL. Functional characterization of p7 viroporin from hepatitis C virus produced in a cell-free expression system. Protein Expr Purif. 2016;118:83–91. doi:10.1016/j.pep.2015.10.004. PMID:26477501.
   PubMed Web of Science ®Google Scholar
• Sjögren J, Struwe WB, Cosgrave EFJ, Rudd PM, Stervander M, Allhorn M, Hollands A, Nizet V, Collin M. EndoS 2 is a unique and conserved enzyme of serotype M49 group A Streptococcus that hydrolyses N-linked glycans on IgG and α 1 -acid glycoprotein. Biochem J. 2013;455:107–18. doi:10.1042/BJ20130126. PMID:23865566.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan B, Qasba PK. Structure-based design of β1,4-galactosyltransferase I (β4Gal-T1) with equally efficient N-acetylgalactosaminyltransferase activity: Point mutation broadens β4Gal-T1 donor specificity. J Biol Chem. 2002;277:20833–9. doi:10.1074/jbc.M111183200. PMID:11916963.
   PubMed Web of Science ®Google Scholar
• Joubert N, Viaud-Massuard M-C, Respaud R. Novel antibody-drug conjugates and the use of same in therapy, WO2015004400, 2015.
   Google Scholar
• Kroiss A, Vincent S, Decaussin-Petrucci M, Meugnier E, Viallet J, Ruffion A, Chalmel F, Samarut J, Allioli N. Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2. Oncogene. 2015;34:2846–55. doi:10.1038/onc.2014.222. PMID:25065599.
   PubMed Web of Science ®Google Scholar
• De Groot AS, Moise L, Mcmurry JA, Wambre E, Van Overtvelt L, Moingeon P, Scott DW, Martin W, Cd CD, Foxp H. Activation of natural regulatory T cells by IgG Fc – derived peptide “ Tregitopes. T Reg depletion. October 2008;112:3303–11.
   Google Scholar
• Frindel M, Camus N, Rauscher A, Bourgeois M, Alliot C, Barré L, Gestin JF, Tripier R, Faivre-Chauvet A. Radiolabeling of HTE1PA: A new monopicolinate cyclam derivative for Cu-64 phenotypic imaging. In vitro and in vivo stability studies in mice. Nucl Med Biol. 2014;41:e49–57. doi:10.1016/j.nucmedbio.2013.12.009. PMID:24440584.
   PubMedGoogle Scholar
• El Alaoui S, Thomas V. mTG substrates for covalent conjugation of compounds, US2016361434, 2016.
   Google Scholar
• Dennler P, Chiotellis A, Fischer E, Brégeon D, Belmant C, Gauthier L, Lhospice F, Romagne F, Schibli R. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates. Bioconjug Chem. 2014;25:569–78. doi:10.1021/bc400574z. PMID:24483299.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, et al. TP53 loss creates therapeutic vulnerability in colorectal cancer. Nature. 2015;520:697–701. doi:10.1038/nature14418. PMID:25901683.
   PubMed Web of Science ®Google Scholar
• Bouchard H, Brun M, Commerçon A, Zhang J. Novel conjugates, preparation thereof, and therapeutic use thereof, WO2011001052, 2011.
   Google Scholar
• Kozlowski S, Swann P. Current and future issues in the manufacturing and development of monoclonal antibodies. Adv Drug Deliv Rev. 2006;58:707–22. doi:10.1016/j.addr.2006.05.002. PMID:16828921.
   PubMed Web of Science ®Google Scholar
• Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, Stelte-Ludwig B, Mayer-Bartschmid A, Unterschemmann K, Bruder S, Linden L, et al. Anetumab Ravtansine: A novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther. 2014;13:1537–48. doi:10.1158/1535-7163.MCT-13-0926. PMID:24714131.
   PubMed Web of Science ®Google Scholar
• Tiberghien AC, Levy J-NN, Masterson LA, Patel NV, Adams LR, Corbett S, Williams DG, Hartley JA, Howard PW. Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload. ACS Med Chem Lett. 2016;7:983–7. doi:10.1021/acsmedchemlett.6b00062. PMID:27882195.
   PubMed Web of Science ®Google Scholar
• Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, Hunter JH, Leiske CI, Miyamoto JB, Nicholas ND, et al. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem. 2013;24:1256–63. doi:10.1021/bc400217g. PMID:23808985.
   PubMed Web of Science ®Google Scholar
• Loganzo F, Tan X, Sung M, Jin G, Myers JS, Melamud E, Wang F, Diesl V, Follettie MT, Musto S, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015;14:952–63. doi:10.1158/1535-7163.MCT-14-0862. PMID:25646013.
   PubMed Web of Science ®Google Scholar
• Deslandes A. Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies. MAbs. 2014;6:859–70. doi:10.4161/mabs.28965. PMID:24852950.
   PubMed Web of Science ®Google Scholar
• Wang J, Song P, Schrieber S, Liu Q, Xu Q, Blumenthal G, Amiri Kordestani L, Cortazar P, Ibrahim A, Justice R, et al. Exposure–response relationship of T-DM1: Insight into dose optimization for patients With HER2-positive metastatic breast cancer. Clin Pharmacol Ther. 2014;95:558–64. doi:10.1038/clpt.2014.24. PMID:24488143.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853–62. doi:10.1016/S0140-6736(15)60165-9. PMID:25796459.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O'Brien S, Wang K, Wang T, et al. Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740–53. doi:10.1056/NEJMoa1509277. PMID:27292104.
   PubMed Web of Science ®Google Scholar
• Hamblett KJ, Senter PD, Chace DF, Hamblett KJ, Senter PD, Chace DF, Sun MMC, Lenox J, Cerveny CG, Kissler KM, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10:7063–70.
   PubMed Web of Science ®Google Scholar
• Burke PJ, Hamilton JZ, Jeffrey SC, Hunter JH, Doronina SO, Okeley NM, Miyamoto JB, Anderson ME, Stone IJ, Ulrich ML, et al. Optimization of a PEGylated glucuronide-monomethylauristatin E linker for antibody–drug conjugates. Mol Cancer Ther [Internet]. 2017;16:116–23. Available from: http://mct.aacrjournals.org/lookup/doi/10.1158/1535-7163.MCT-16-0343 doi:10.1158/1535-7163.MCT-16-0343.
   PubMed Web of Science ®Google Scholar
• Prashad AS, Nolting B, Patel V, Xu A, Arve B, Letendre L. From R&D to Clinical Supplies. Org Process Res Dev. 2017;21:590–600. doi:10.1021/acs.oprd.7b00020.
   Web of Science ®Google Scholar